Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Gregory M. Weinhoff Sells 11,742 Shares

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 11,742 shares of the stock in a transaction on Monday, January 27th. The stock was sold at an average price of $16.47, for a total value of $193,390.74. Following the completion of the sale, the insider now owns 159,782 shares in the company, valued at $2,631,609.54. This trade represents a 6.85 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Centessa Pharmaceuticals Price Performance

Shares of Centessa Pharmaceuticals stock opened at $16.59 on Wednesday. The business’s 50-day moving average price is $16.79 and its 200-day moving average price is $15.01. The firm has a market capitalization of $2.19 billion, a PE ratio of -10.84 and a beta of 1.53. Centessa Pharmaceuticals plc has a 12 month low of $7.38 and a 12 month high of $18.97. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.42) by $0.05. Sell-side analysts forecast that Centessa Pharmaceuticals plc will post -1.6 EPS for the current fiscal year.

Institutional Trading of Centessa Pharmaceuticals

Several hedge funds have recently added to or reduced their stakes in the business. XTX Topco Ltd purchased a new position in shares of Centessa Pharmaceuticals in the second quarter worth about $148,000. The Manufacturers Life Insurance Company grew its position in Centessa Pharmaceuticals by 30.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 140,894 shares of the company’s stock worth $1,272,000 after acquiring an additional 32,846 shares during the last quarter. Quarry LP increased its stake in Centessa Pharmaceuticals by 47.8% in the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock worth $87,000 after purchasing an additional 3,108 shares during the period. Perceptive Advisors LLC lifted its position in Centessa Pharmaceuticals by 27.6% in the second quarter. Perceptive Advisors LLC now owns 3,933,307 shares of the company’s stock valued at $35,518,000 after purchasing an additional 850,000 shares during the last quarter. Finally, Nantahala Capital Management LLC purchased a new stake in shares of Centessa Pharmaceuticals during the second quarter valued at approximately $4,064,000. 82.01% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on CNTA. Guggenheim raised their price target on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. TD Cowen assumed coverage on shares of Centessa Pharmaceuticals in a research note on Tuesday, January 7th. They issued a “buy” rating on the stock. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $25.83.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.